Post-Transplant Cyclophosphamide GVHD Prophylaxis Has a Unique Vascular Toxicity Compared to Abatacept Containing Regimens.

Key Points

• Cyclophosphamide prophylaxis is associated with distinct vascular toxicity compared to abatacept-based regimens.
• Graft-versus-host disease (GVHD) prophylaxis was assessed in patients receiving different treatments, focusing on vascular effects.
• Observational analysis focuses on cytokine levels and their relation to vascular toxicity in transplant settings.
• Understanding these toxicities may guide clinicians in selecting appropriate GVHD prophylactic strategies.